Related Experiment Video
Updated: Jun 6, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
The Predictive and Prognostic Value of the Systemic Immune-Inflammation Index for Congestive Heart Failure
Zhihao Zheng1,2,3, Shanshan Shi1,2,3, Zechen Liu1,2,3
1Cardiometabolic Medicine Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 100037 Beijing, China.
Insights
The systemic immune-inflammatory index (SII) is linked to a higher prevalence of congestive heart failure (CHF) and poorer outcomes in patients with CHF. This novel biomarker may aid in CHF prevention and management.
Area of Science:
- Cardiology
- Immunology
- Biomarker research
Background:
- The systemic immune-inflammatory index (SII), a ratio of neutrophils and platelets to lymphocytes, is an emerging biomarker.
- Its association with congestive heart failure (CHF) prevalence and prognosis remains unclear.
- This study investigates the relationship between SII and CHF.
Purpose of the Study:
- To determine the association between SII levels and the prevalence of CHF in the general population.
- To evaluate the prognostic significance of SII for long-term outcomes in patients diagnosed with CHF.
Main Methods:
- Utilized data from 57,500 participants in the National Health and Nutritional Examination Surveys.
- Employed cross-sectional analysis for prevalence and prospective longitudinal analysis for prognosis with a 5.4-year follow-up.
- Statistical methods included multivariate logistic regression, Cox proportional hazards models, and restricted cubic spline (RCS) analysis.
Main Results:
- A higher prevalence of CHF was observed in participants with high SII levels (OR 1.24; 95% CI: 1.05, 1.45).
- Among CHF patients, high SII was significantly associated with increased risk of all-cause mortality (HR 1.44; 95% CI: 1.14, 1.81) and cardiovascular death (HR 1.31; 95% CI: 1.08, 1.58).
- RCS analysis confirmed a positive correlation between SII and CHF prevalence and mortality risk.
Conclusions:
- This study is the first to demonstrate a link between high SII and increased CHF prevalence.
- Elevated SII levels indicate a poorer prognosis for patients with congestive heart failure.
- SII may serve as a valuable biomarker for CHF prevention and management strategies.
Background:
The systemic immune-inflammatory index (SII), calculated by (platelet count × neutrophil count)/lymphocyte count, is a novel biomarker with predive and prognostic value in numerous diseases. However, the relationship between SII and congestive heart failure (CHF) is not clear. This study aims to document the association of SII with the prevalence of CHF in the whole population and the long-term prognosis in CHF patients.
Methods:
This study included 57,500 participants in the National Health and Nutritional Examination Surveys, who were categorized into 3 categories based on their SII levels. A cross-sectional study was conducted to examine the relationship between SII and CHF prevalence in the whole population, followed by a prospective longitudinal study with a 5.4-year follow-up period for CHF patients to assess the predictive significance of SII for CHF. The main focus of the longitudinal study was on all-cause death as the primary outcome, with cardiovascular (CV) death as the secondary outcome. Associations were estimated using multivariate logistic regression and Cox proportional hazards models. The dose-response relationship was assessed with the restricted cubic spline (RCS) analysis.
Results:
In the cross-sectional analysis, there were 1927 (3.35%) participants diagnosed with CHF. The high SII group showed a significantly higher prevalence of CHF than the low SII group (odds ratio (OR) 1.24, 95% confidence interval (CI): 1.05, 1.45). In the longitudinal analysis, 882 all-cause deaths including 379 CV deaths were collected among CHF patients, and high SII was associated with a significant increase in the risk of all-cause death (hazard ratio (HR) 1.44; 95% CI: 1.14, 1.81) and CV death (HR 1.31; 95% CI: 1.08, 1.58). RCS confirmed the positive correlation of SII with the prevalence of CHF in the whole population, as well as the mortality risk in CHF patients.
Conclusions:
This study is the first to reveal that high SII was related to a high prevalence of CHF and a poor prognosis in CHF patients. These findings underscore the potential role of SII in the prevention and management of CHF.
More Related Videos
08:51Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Myocarditis I: Introduction
Myocarditis II: Clinical features and Diagnostic Tests
Pathophysiology of Heart Failure
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies